Sovateltide
Sovateltide
Chemical compound
Sovateltide (development names IRL-1620 and PMZ-1620,[1] sold in India under the brand name Tyvalzi)[2] is a synthetic analog of endothelin-1 that works as a selective endothelin-B receptor agonist. In May 2023, it was approved in India to treat acute ischemic stroke. The drug was developed by Pharmazz.[2] Sovateltide stimulates neural progenitor cells in the brain and promotes neurovascular remodeling by forming new neurons (neurogenesis) and blood vessels (angiogenesis).[3][4] Sovateltide also protects neural mitochondria and enhances their biogenesis.[5]